Hemophagocytic Lymphohistiocytosis Thought to Be due to Undifferentiated Connective Tissue Disease Treated With Ruxolitinib: A Case Report

Emily Vachon, Heena Birbal Jain, Suzanna Kitten, Nikhat Kaura · 2026

Read Hemophagocytic Lymphohistiocytosis Thought to Be due to Undifferentiated Connective Tissue Disease Treated With Ruxolitinib: A Case Report by Emily Vachon, Heena Birbal Jain, Suzanna Kitten, Nikhat Kaura (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13677135.txt.

Description

Emily Vachon and co-authors report a long hunt for the cause of a dangerous immune storm in a young woman. Their 2026 case report concerns hemophagocytic lymphohistiocytosis, a syndrome where inflammation runs out of control. The patient, aged twenty-four, was first suspected of reacting to a common drug. Stopping it did not help, and tests for infection and cancer came back empty.

Treatment after treatment failed: a chemotherapy drug, high-dose steroids, an antibody therapy, and plasma exchange all fell short. Clues finally pointed to an undefined connective tissue process, with a positive general antibody test and inflamed finger joints but no specific antibodies. A drug called ruxolitinib then turned the case: she stabilized on it and remains stable more than five years later. The authors note the drug is still classed as salvage therapy, and offer the case as evidence when standard care fails.

Catalog record

CREATOREmily Vachon, Heena Birbal Jain, Suzanna Kitten, Nikhat Kaura
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE18 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13677135

Browse the full library · About the Tower of Babel